Japan Psoriasis Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Severity, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Japan · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$2.19 BnPlaceholder estimate
Estimate 2025$2.34 Bn6.8% of the global market
Projected 2034$4.38 Bn 87%Adds $2.04 Bn over 9 forecast years
CAGR 2025–20347.2%Faster than 31% of 180 Pharmaceuticals markets here
26 in JapanSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Japan Psoriasis Treatment Market Analysis Executive Summary
Psoriasis treatments clear red, scaly skin patches using creams, light therapy, pills and biologic injections.
Key segments of the psoriasis Treatment market include drug class (IL-17 Inhibitors, IL-23 Inhibitors and TNF Inhibitors) and severity (Mild and Moderate to Severe).
Japan Psoriasis Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Japan Psoriasis Treatment Market Dynamics
Market Growth Drivers
Rising interest in appearance, social media, more affordable treatments and new minimally invasive options are driving the psoriasis Treatment market. More clinics and chains are opening in fast-growing cities.
Opportunity
Treatments for men, at-home options, digital consultations and growth in Asia and the Middle East give the psoriasis Treatment market room to grow.
Market Restraints
Treatments are mostly paid out of pocket, results and safety vary between providers, and economic slowdowns can reduce spending on the psoriasis Treatment market.
Competitive Landscape for Psoriasis Treatment Market in Japan
The psoriasis Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Psoriasis Treatment Market in Japan
Psoriasis Treatment in Japan: rules, payment and research
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).[2] ClinicalTrials.gov lists 26 studies on Psoriasis Treatment that are recruiting, active or about to start in Japan.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for psoriasis Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug Class
4.2 By Severity
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Johnson & Johnson
7.2 AbbVie
7.3 Novartis
7.4 Eli Lilly and Company
7.5 UCB
7.6 Amgen
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The psoriasis Treatment market can be segmented based on various criteria, including drug class, severity and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Psoriasis Treatment right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Psoriasis Treatment in context
Japan compared
Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
How big is the Psoriasis Treatment market in Japan?
Placeholder estimate: about $2.34 Bn in 2025, rising to about $4.38 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Psoriasis Treatment market in Japan growing?
Placeholder estimate: about 7.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Psoriasis Treatment market report cover?
The report splits the market by drug class (IL-17 Inhibitors, IL-23 Inhibitors, TNF Inhibitors, Oral Drugs and more), severity (Mild, Moderate to Severe) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Psoriasis Treatment market?
Key players include Johnson & Johnson, AbbVie Inc., Novartis AG, Eli Lilly and Company, UCB and Amgen Inc..
What is driving the Psoriasis Treatment market?
Rising interest in appearance, social media, more affordable treatments and new minimally invasive options are driving the psoriasis Treatment market. More clinics and chains are opening in fast-growing cities.
Who regulates Psoriasis Treatment in Japan?
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW). Source: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
How is healthcare paid for in Japan?
Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices). Source: Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
How many clinical trials on Psoriasis Treatment are running in Japan?
26 studies are recruiting, active or about to start in Japan, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
How much research is published on Psoriasis Treatment?
PubMed lists 926 papers on Psoriasis Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Japan 
China
India
US
Canada
Germany
Brazil
France
Italy
UK
Ecuador
Spain
Mexico
Saudi Arabia
Australia
New Zealand
Russia
South Africa
UAE
Egypt
Philippines
Malaysia
Hong Kong
Thailand
Singapore
Kenya
Sun Pharmaceutical Industries Ltd.
Hikma Pharmaceuticals PLC
Bristol-Myers Squibb
Fresenius SE & CO
Takeda Pharmaceutical Company Ltd